US 12,133,885 B2
Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
Peter Leonardi, New York, NY (US); Elin Martina Pola, Agunnaryd (SE); and Jeffrey Babad, Mamaroneck, NY (US)
Assigned to OMNICYTE, New York, NY (US)
Filed by OMNICYTE, New York, NY (US)
Filed on Oct. 13, 2022, as Appl. No. 18/046,267.
Application 18/046,267 is a division of application No. 16/844,271, filed on Apr. 9, 2020, granted, now 11,471,518.
Application 16/844,271 is a continuation of application No. 15/558,918, granted, now 10,660,948, issued on May 6, 2020, previously published as PCT/US2016/002320, filed on Mar. 18, 2016.
Claims priority of provisional application 62/134,933, filed on Mar. 18, 2015.
Prior Publication US 2023/0181706 A1, Jun. 15, 2023
Int. Cl. A61K 39/00 (2006.01); A61K 39/385 (2006.01); A61P 35/00 (2006.01); C07K 14/005 (2006.01)
CPC A61K 39/0011 (2013.01) [A61K 39/001188 (2018.08); A61K 39/385 (2013.01); A61P 35/00 (2018.01); C07K 14/005 (2013.01); A61K 2039/6075 (2013.01); C07K 2319/00 (2013.01); C12N 2770/36134 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method for treating a disease or a disorder in a subject, comprising administering to the subject a fusion protein wherein the fusion protein is an isolated or recombinant fusion protein comprising alpha virus surface membrane glycoproteins E1, E2, a linker and at least one tumor associated antigen, wherein the fusion protein comprises: (i) an amino acid sequence having at least 98% identity to SEQ ID NO:1, or (ii) at least amino acid residues at positions 66-978 of SEQ ID NO:1.